The pharmaceutical company Pfizer announced last Wednesday that it will evaluate the efficacy of its anticovid vaccine in a large-scale study by vaccinating all residents over 12 years of age in a city in Brazil, informs Reuters.
“The initiative is the first and only of its kind to be done in collaboration with a pharmaceutical company in a developing country, “said Pfizer.
During the large-scale study, which will be carried out in Toledo, a city of about 143,000 inhabitants of the state of Paraná, in collaboration with the National Immunization Program of Brazil and local authorities, Pfizer will study the transmission of the coronavirus in a “real life scenario”. Since one of the main objectives of the study is to evaluate the duration of protection provided by the drug, vaccinated people will be monitored for a period of up to one year.
“Here we believe in science and we regret the almost 600,000 deaths that occurred in the country,” said Toledo Mayor Beto Lunitti.
According to estimates, at the moment in Toledo almost the 98 % of the population over 12 years of age have already received the first dose of coronavirus vaccines.
Another similar study was carried out by the Butantan Institute in the city of Serrana, in the state of Sao Paulo, where mass immunization with the CoronaVac vaccine from the Chinese pharmaceutical company Sinovac Biotech was ordered. According to data from the Institute, in May, mass vaccination allowed reduce by 95% deaths from covid-19.
Disclaimer: This article is generated from the feed and not edited by our team.